Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program

• Zenas Biopharma outlined a near-term regulatory path for obexelimab in IgG4-RD, with an FDA decision expected by May 2027.
• Phase 3 INDIGO in IgG4-RD met its primary endpoint, cutting flare risk 56% versus placebo; 73% of treated patients were flare-free.
• Key secondary endpoints favored obexelimab, including 37.1% complete remission at week 52 versus 19.6% for placebo.
• Orelabrutinib, a BTK inhibitor, is in Phase 3 for PPMS and naSPMS, with trials initiated in 3Q 2025 and 1Q 2026.
• Pipeline updates flagged clinical data expected by year-end 2026 for oral IL-17 inhibitor ZB021, with additional readouts in 2027 for ZB022 and ZB014.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.